Axsome Therapeutics, Inc. research snapshot
AXSM AI stock analysis currently reads Axsome Therapeutics, Inc. as a commercial-stage central nervous system biopharma with fast Auvelity-led product growth, a newly launched Alzheimer disease agitation indication, three marketed CNS medicines, an expanding late-stage pipeline, and material profitability and valuation risk. At the August 3, 2026 data cutoff, AXSM closed at $217.99 on July 31, 2026 with a verified market capitalization of about $11.22 billion using 51.46 million shares. FY2025 total net product revenue reached $638.5 million, Q1 2026 revenue was $191.2 million, and the company was still GAAP loss-making with about $305.1 million of cash at March 31, 2026. Auvelity won FDA approval for agitation associated with dementia due to Alzheimer disease in April 2026 with a commercial launch in June, the AXS-12 narcolepsy NDA was accepted for filing in July 2026 with a May 1, 2027 PDUFA date, and Q2 2026 results are scheduled for August 10, 2026. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$217.99
Market cap
$11.22 billion
AI score
62 / 100
Rating
High-growth commercial CNS biotech with a new Alzheimer agitation launch, AXS-12 regulatory progress, and high valuation plus loss risk
Trend status
Long-term uptrend intact, short-term pullback after the late-July selloff toward the $216 to $218 support zone
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Axsome sells CNS medicines led by Auvelity in major depressive disorder and Alzheimer disease agitation, plus Sunosi for excessive daytime sleepiness and Symbravo for acute migraine. | High |
| Moat | The moat comes from differentiated mechanisms, patents, labels, payer coverage, and commercial infrastructure, and it widened in 2026 with the Auvelity Alzheimer agitation approval. It is not a network-effect franchise and must still be defended product by product. | Medium |
| Management | Founder-CEO Herriot Tabuteau has converted a CNS development story into a multi-product commercial company and secured the Auvelity Alzheimer agitation approval and AXS-12 NDA acceptance in 2026. Capital allocation is still judged by the path to cash-flow positivity and pipeline ROI. | Medium-high |
| Financial trend | FY2025 total net product revenue rose to $638.5 million (+66% YoY), Q1 2026 revenue reached $191.2 million (+57% YoY), and TTM revenue was about $708 million, while FY2025 net loss was $183.2 million and Q1 2026 net loss was $64.5 million. | High |
| Valuation | At $217.99, AXSM traded near 15.8x TTM revenue of about $708 million, about 11.5x the roughly $979 million 2026 revenue consensus, near 15.7x EV-to-revenue, with trailing PE still negative on TTM EPS near -$3.73. | Medium-high |
| Technical trend | ChartMill showed a long-term uptrend and short-term downtrend, with price near $217.99 after a -7.1% close on July 31, support around $216 to $218, resistance near $233 to $241, SMA50 near $238.6, and SMA200 near $185.2. | Medium |
| Risk level | Main risks are Auvelity concentration, Alzheimer agitation launch execution, Q2 2026 results on August 10, SG&A intensity, continued losses, competitive CNS drugs, clinical or regulatory setbacks, dilution, and multiple compression after a strong run. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech stocks reprice around launch metrics, trial data, FDA updates, payer news, and earnings. | High data confidence |
| Investment certainty | Medium-low certainty. Product growth, the Alzheimer agitation launch, and AXS-12 progress are real positives, but durable free cash flow and a justified premium multiple still depend on multi-year commercial and pipeline execution. | Medium-low |
AXSM AI stock forecast
The AXSM AI stock forecast uses scenario ranges around the $217.99 July 31, 2026 close. Because FY2025 GAAP EPS was -$3.68, the mandatory three-scenario EPS tool produces non-economic negative targets and is not used as a price forecast. An illustrative path-to-profit framework using a $5.00 EPS base with bull, base, and bear growth and PE assumptions produced roughly $417, $199, and $68. Commercial and launch-driven ranges below are more decision-relevant for a still-loss-making CNS company. The consensus 12-month target was about $282.51 across 21 analysts with a Strong Buy rating.
$300 to $360
More likely if Auvelity keeps scaling in MDD and the Alzheimer agitation launch ramps well through 2026, Symbravo coverage and scripts accelerate, the AXS-12 filing progresses toward its May 1, 2027 PDUFA date, Q2 2026 results beat, and investors keep paying a premium growth multiple as losses narrow.
$180 to $250
More likely if product revenue keeps growing toward the roughly $979 million 2026 analyst revenue area but SG&A and R&D keep AXSM loss-making, the Alzheimer agitation launch starts more slowly, and the market waits for clearer cash-flow positivity and a deeper multiple.
$100 to $160
More likely if Auvelity growth slows, the Alzheimer agitation launch or Q2 2026 results disappoint, payer pressure cuts net price, a material pipeline readout or regulatory event fails, cash burn forces dilutive financing, or the stock rerates toward a lower sales multiple.
AXSM AI technical analysis
AXSM AI technical analysis is cautious-to-constructive as of the August 3, 2026 cutoff. AXSM closed at $217.99 on July 31, 2026 after a -7.1% session that followed a pullback from the $252 to $260 area. ChartMill listed a long-term uptrend, short-term downtrend, support from $216.47 to $217.98, resistance near $233.34 to $241.01, RSI near 38.24, MACD near -1.56, and SMA(20)/SMA(50)/SMA(200) near $236.11, $238.60, and $185.21.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $217.99 | July 31, 2026 close used for August 3, 2026 research and market cap math with 51.46 million shares. |
| Near support | $216 to $218 | ChartMill listed a support zone from $216.47 to $217.98 formed by multiple trend lines in multiple time frames. |
| Secondary support | $208 to $213 | The 13-week range low is near $208.50 and the 60-day low near $213.20, useful if the first support zone fails. |
| Deeper support | $174 to $185 | ChartMill listed trend-line support near $174.39 and the rising SMA200 was near $185.21, the area for a full trend-break review. |
| Moving averages | Mixed short term, constructive long term | ChartMill SMA(5)/SMA(20)/SMA(50)/SMA(200) were near $230.52, $236.11, $238.60, and $185.21. Price sat below the 5-, 20-, and 50-day averages and well above the 200-day average. |
| Resistance | $233 to $241, then $250 | ChartMill listed resistance from $233.34 to $241.01 built from trend lines and moving averages, with an additional daily horizontal level near $249.77. The 52-week high area sits near $260.19. |
| Momentum | Cooling after a strong multi-month run | RSI near 38 and a negative MACD near -1.56 signal short-term weakness inside a still-positive longer-term trend. Weekly RSI near 54 and weekly MACD near -2.42 also cooled. |
| Volume | Event-sensitive biotech volume | Average volume near 718,000 to 900,000 shares. Compare volume on the August 10, 2026 Q2 report, Auvelity Alzheimer launch updates, FDA news, and pipeline readouts. |
| Volatility | High for a commercial-growth biotech | ATR near 4.6% to 4.7% and a 52-week range from $96.09 to $260.19 show large swings around commercial, regulatory, and clinical catalysts. |
| Invalidation | Close below $216, then $208 | A decisive close below the $216 support zone would weaken the swing setup. A break below $208 would require a deeper thesis review near the 13-week low. |
AXSM AI trading strategy
The AXSM AI trading strategy is a rules-based framework for a high-growth CNS biotech with product concentration, launch risk, regulatory milestones, and event volatility. It is not personal advice and should be paired with live quotes, filings, position sizing, the August 10, 2026 Q2 report, and clinical or commercial event checks.
Watch for AXSM to hold above the $216 to $218 support zone, reclaim the $230 to $236 short moving averages, and challenge the $233 to $241 resistance area and then $250 with confirming volume and no negative launch, Q2, or trial news.
A close below $216 should invalidate the short-term swing setup. A close below $208 should force a full review of Auvelity growth, the Alzheimer agitation launch, cash runway, and valuation assumptions.
If AXSM holds support near $216 to $218 without a new commercial, payer, regulatory, or clinical problem, compare the pullback with Q1 product growth, Auvelity Alzheimer launch traction, Symbravo coverage gains, cash burn, and analyst target history.
Do not treat every pullback as mean reversion. Biotech support levels can fail fast when launch metrics, reimbursement, FDA decisions, or trial news change the growth narrative.
Track Auvelity MDD and Alzheimer agitation sales, Sunosi prescriptions and royalties, Symbravo coverage and scripts, SG&A spend, R&D milestones for solriamfetol, AXS-05, AXS-12, and AXS-14, the May 1, 2027 AXS-12 PDUFA date, cash of $305.1 million at March 31, 2026, and debt near $188 million.
Reduce confidence if valuation depends mainly on a premium sales multiple rather than durable net-price growth, controllable opex, a credible path to cash-flow positivity, and clean Q2 2026 results on August 10.
Investment research summary
Axsome turns CNS science, regulatory approvals, and commercial execution into product revenue from medicines for depression, Alzheimer agitation, sleepiness disorders, and migraine. Customers and payers pay when efficacy, access, and tolerability beat alternatives for those conditions.
The moat is strongest where mechanism differentiation, labels, patents, payer coverage, and sales relationships reinforce each other, and it gained ground with the Auvelity Alzheimer agitation approval. It narrows if generics, competing branded CNS drugs, or weaker net pricing erode growth in Auvelity, Sunosi, or Symbravo.
The thesis fails if Auvelity growth slows, the Alzheimer agitation launch underwhelms, Q2 2026 results disappoint, SG&A stays too high for cash-flow positivity, pipeline programs fail, financing dilutes holders, or the sales multiple compresses before profits arrive.
Management has converted a CNS development story into a multi-product commercial company and delivered the Auvelity Alzheimer agitation approval plus an accepted AXS-12 NDA in 2026. The next test is allocating capital across sales force expansion, late-stage trials, and balance-sheet risk while still guiding toward cash-flow positivity on the current plan.
CNS disorders remain large, under-served markets with durable demand for better oral options, and the Auvelity Alzheimer agitation approval expands the addressable patient base. The opportunity is long-term, but pricing scrutiny, competitive launches, and clinical failure rates keep the industry high-risk.
AXSM is priced for continued high product growth and successful pipeline conversion, near 15.8x TTM revenue at the July 31 close. Margin of safety is limited if investors require profitability sooner, but improves if the Alzheimer agitation launch and pipeline milestones expand durable revenue without heavy dilution.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| AXSM price | $217.99 close on July 31, 2026, down 7.1% on the session | Yahoo Finance, StockAnalysis, and ChartMill quotes | August 3, 2026 |
| Market capitalization | $11.22 billion, verified as $217.99 x 51.46 million shares | financial_rigor.py market cap verification | August 3, 2026 |
| Shares outstanding | 51.42 million at March 31, 2026 company report; 51.46 million used in market data snapshots | Axsome Q1 2026 release and Yahoo key statistics cross-check | August 3, 2026 |
| FY2025 total net product revenue | $638.5 million, up 66% year over year | Axsome FY2025 earnings release coverage | August 3, 2026 |
| FY2025 product mix | Auvelity $507.1M, Sunosi $124.8M, Symbravo $6.6M | Axsome FY2025 product sales disclosures | August 3, 2026 |
| FY2025 net loss and EPS | $183.2 million net loss, or $(3.68) per share | Axsome FY2025 earnings release | August 3, 2026 |
| Q1 2026 total net product revenue | $191.2 million, up 57% year over year | Axsome Q1 2026 earnings release | August 3, 2026 |
| Q1 2026 product mix | Auvelity $153.2M, Sunosi $33.9M, Symbravo $4.1M | Axsome Q1 2026 earnings release | August 3, 2026 |
| Q1 2026 net loss, cash, and debt | Net loss $64.5 million; cash $305.1 million; short-term borrowings $70.0 million plus long-term loan payable about $117.9 million | Axsome Q1 2026 balance sheet and income statement | August 3, 2026 |
| Auvelity Alzheimer agitation approval and launch | FDA approved Auvelity for agitation associated with dementia due to Alzheimer disease in April 2026; commercial launch started June 2026 | Axsome Q1 2026 business update and BMO initiation coverage | August 3, 2026 |
| AXS-12 narcolepsy NDA status | FDA accepted the AXS-12 new drug application for cataplexy in narcolepsy on July 15, 2026 with a PDUFA target action date of May 1, 2027 and no planned advisory committee | Axsome AXS-12 NDA acceptance press release | August 3, 2026 |
| TTM financials and valuation | Revenue about $708.24 million, net loss about $188.3 million, diluted EPS near -$3.73, a trailing P/S near 15.8x, and EV-to-revenue near 15.7x at the July 31 close | Yahoo Finance and StockAnalysis statistics | August 3, 2026 |
| Analyst consensus | Strong Buy average rating across 21 analysts with a 12-month target near $282.51 (range $242 to $380). Mizuho lowered its target to $306 on July 31, 2026, Jefferies raised its target to $380, and BMO initiated coverage with a $310 target citing the Auvelity Alzheimer agitation approval | StockAnalysis and Yahoo Finance analyst pages | August 3, 2026 |
| Technical support and resistance | Support $216.47 to $217.98 and $174.39 to $185; resistance $233.34 to $241.01 and $249.77; SMA50 $238.60; SMA200 $185.21 | ChartMill technical analysis | August 3, 2026 |
| Q2 2026 results date | Axsome will report second quarter 2026 financial results on August 10, 2026 | Axsome Q2 2026 results date announcement | August 3, 2026 |
This AXSM AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong if financial results, clinical data, regulation, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
